---
title: "Context Therapeutics sells 14,705,882 shares for about $15 million to MPM"
url: "https://aibio.space/news/context-therapeutics-sells-14-705-882-shares-about-15-million-mpm/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-12-23"
section: "Financings"
tickers: "NASDAQ:CNTX"
source: "https://www.sec.gov/Archives/edgar/data/1842952/000184295224000087/cntx-20241223.htm"
summary: "The shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024."
---

By the aibio.space news desk.

Sources

- [Context Therapeutics Inc. 8-K (2024-12-23)](https://www.sec.gov/Archives/edgar/data/1842952/000184295224000087/cntx-20241223.htm)

[CNTX](https://aibio.space/companies/context-therapeutics/)

2024-12-23

# Context Therapeutics sells 14,705,882 shares for about $15 million to MPM BioImpact

Tickers [CNTX](https://aibio.space/companies/context-therapeutics/)

The shares were sold through the company's sales agreement with Leerink Partners on December 23, 2024.

## Key facts

- **Company**: Context Therapeutics Inc. (NASDAQ: CNTX)

- **News type**: Financings

- **Primary source**: [Context Therapeutics Inc. 8-K (2024-12-23)](https://www.sec.gov/Archives/edgar/data/1842952/000184295224000087/cntx-20241223.htm)

*Glass office towers seen from below. CC0, via rawpixel. The picture shows the field, not the companies named.*

Context Therapeutics Inc. sold 14,705,882 shares of its common stock on December 23, 2024, for aggregate gross proceeds of approximately $15 million, according to a [Form 8-K filing](https://www.sec.gov/Archives/edgar/data/1842952/000184295224000087/cntx-20241223.htm). Gross proceeds are the amount raised before fees and expenses are deducted.

The Philadelphia company sold the shares under a sales agreement with Leerink Partners LLC dated December 2, 2024. Leerink acted as the company's agent for the sale.

According to the filing, the agent informed the company that the shares were purchased by MPM BioImpact LLC.

The company reported the sale under Item 8.01 of Form 8-K, the section used for other events, and filed the report on the same day the shares were sold. Context Therapeutics' common stock, par value $0.001 per share, trades on The Nasdaq Stock Market under the symbol CNTX. The company identifies itself in the filing as an emerging growth company.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CNTX

Context Therapeutics Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/context-therapeutics-sells-14-705-882-shares-about-15-million-mpm/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Context Therapeutics sells 14,705,882 shares for about $15 million to MPM", 2024-12-23, https://aibio.space/news/context-therapeutics-sells-14-705-882-shares-about-15-million-mpm/